Last reviewed · How we verify

NCT06261931: STAR

Severity Over Time of Early Forms of Spondyloarthritis

Not yet recruiting Last updated 15 February 2024
What this trial tests

trial testing Diagnostic assessment in Spondyloarthritis in 387 participants. Not yet recruiting.

Timeline
12 February 2024
Primary endpoint
28 February 2026
28 February 2044

Quick facts

Lead sponsorFondazione Policlinico Universitario Agostino Gemelli IRCCS
StatusNot yet recruiting
Study typeOBSERVATIONAL
Enrollment387
Start date12 February 2024
Primary completion28 February 2026
Estimated completion28 February 2044
Sites1 location across Italy

Drugs / interventions tested

Conditions studied

Sponsor

Fondazione Policlinico Universitario Agostino Gemelli IRCCS

Who can join

18 and older, any sex, with Spondyloarthritis or Spondyloarthritis, Axial. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Spondyloarthritis (SpA) is a group of chronic inflammatory pathologies whose progression over time is poorly defined, and in particular the clinical and instrumental elements that can predispose to a condition of disease severity are not completely known. It would be important to have an idea of what the predisposing factors are, possibly already at baseline, and possibly also at follow up, of severe disease, so as to be able to act early with more aggressive and targeted therapies on these patients, so as to achieve remission.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Spondyloarthritis

Currently open trials in the same condition.

Other Fondazione Policlinico Universitario Agostino Gemelli IRCCS trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06261931.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing